Pfizer PFE Biopharma — D&A

Similar metrics at other companies

BDXBioPharma Systems — D&A

$27M-15.6%

ATRPharma — D&A

$35.64M+14.4%

AVT

AVTRBioscience & Medtech Products — D&A

$49.2M+12.3%

CAHPharmaceutical and Specialty Solutions — D&A

$70M+59.1%

CVSPharmacy & Consumer Wellness — D&A

$406M+5.7%

CORTD&A

$598K+29.4%

Questions, answered.

What is Pfizer's biopharma — D&A?

Pfizer (PFE) reported biopharma — D&A of $348M in Q1 2026.

How has Pfizer's biopharma — D&A changed year-over-year?

Pfizer's biopharma — D&A increased by 5.1% year-over-year, from $331M to $348M.

What is the long-term trend for Pfizer's biopharma — D&A?

Over 4 years (2021 to 2025), Pfizer's biopharma — D&A has grown at a 15.0% compound annual growth rate (CAGR), from $789M to $1.38B.

What does biopharma — D&A mean?

The systematic allocation of the cost of tangible and intangible assets over their useful lives within the Biopharma segment. It reflects the consumption of capital investments, such as manufacturing facilities and acquired intellectual property.